Pfizer (PFE) Strikes Co-Development Deal with Innovent Biologics (01801.HK) for Oncology Medicines

Pfizer Inc. (NYSE: PFE) and Innovent Biologics (HKEX: 01801) on Friday entered into a strategic collaboration to jointly develop and commercialize oncology medicines, targeting underserved cancer markets in China and globally. Under the agreement, Innovent will gain rights to co-develop select early-stage Pfizer oncology candidates, while Pfizer will access Innovent’s established clinical development and commercialization infrastructure in China. Financial terms were not disclosed, though the companies confirmed the deal includes research and development funding, milestone payments, and royalty streams on future net sales. The partnership seeks to expedite clinical trials and regulatory approvals for novel immuno-oncology therapies by combining Pfizer’s global pipeline with Innovent’s regional expertise and cost-efficient operations. No specific lead drug candidates or timelines were immediately announced.